====== Oligodendroglial tumors epidemiology ======

Incidence of [[oligodendroglial tumors]] is 0.28 per 100,000 for [[age]]s 15–39 years and 0.31 for ages 40 +
((Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C,
Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary brain and other central
nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol.
2017 Nov 6;19(suppl_5):v1-v88. doi: 10.1093/neuonc/nox158. PubMed PMID: 29117289;
PubMed Central PMCID: PMC5693142.
)).

Comprise only ≈ 1% of primary brain tumors. Ratio of male:female = 1.3:1
((Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C,
Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary brain and other central
nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol.
2017 Nov 6;19(suppl_5):v1-v88. doi: 10.1093/neuonc/nox158. PubMed PMID: 29117289;
PubMed Central PMCID: PMC5693142.
)).

Location: > 50% occur in the [[frontal lobe]]s, followed by [[temporal lobe]], [[parietal lobe]] & [[occipital lobe]]s.

They constitute together with mixed [[oligoastrocytoma]] 5–20% of all gliomas
((van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol
Clin. 2007 Nov;25(4):1089-109, ix-x. Review. PubMed PMID: 17964027.)).
----
Data were analyzed from the [[Central Brain Tumor Registry of the United States]] ([[CBTRUS]]) from 2000 to 2013. Age-adjusted incidence rates per 100,000 person-years with 95% confidence intervals (CI) and annual percent changes (APCs) with 95% CI were calculated for [[oligodendroglioma]] (OD) and [[anaplastic oligodendroglioma]] (AOD) by age, sex and race. Survival rates were calculated for age, sex and race using a subset of the CBTRUS data. OD and AOD incidence peaked at 36-40 and 56-60 years, respectively. AOD:OD ratio increased up to age 75. Overall, OD and AOD incidence decreased [OD: APC -3.2 (2000-2013), AOD: -6.5 (2000-2007)]. OD incidence was highest in Whites but decreased significantly (2000-2013: APC -3.1) while incidence in Black populations did not significantly decrease (2000-2013: APC -1.6). Survival rates decreased with advancing age for OD, while persons aged 0-24 had the lowest survival for AOD. The current study reports a decrease in overall OD and AOD incidence from 2000 to 2013. Furthermore, AOD makes up an increasing proportion of oligodendroglial tumors up to age 75. Lower AOD survival in 0-24 years old may indicate molecular differences in pediatric cases. Thus, surveillance of tumor-specific trends by age, race and sex can reveal clinically relevant variations
((Achey RL, Khanna V, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Incidence and
survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the
United States from 2000 to 2013: a CBTRUS Report. J Neurooncol. 2017
May;133(1):17-25. doi: 10.1007/s11060-017-2414-z. Epub 2017 Apr 10. PubMed PMID: 
28397028.
)).
===== References =====